Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

homologous recombination deficiency

  • Home
  • homologous recombination deficiency
Harnessing HRD Testing and MYC Amplification to Optimize PARP Inhibitor Use in BRCA Wild-Type High-Grade Serous Ovarian Carcinoma
Posted innews OB/GYN & Women’s Health Oncology

Harnessing HRD Testing and MYC Amplification to Optimize PARP Inhibitor Use in BRCA Wild-Type High-Grade Serous Ovarian Carcinoma

Posted by MedXY By MedXY 07/15/2026
This article reviews real-world data supporting homologous recombination deficiency (HRD) testing in BRCA1/2 wild-type high-grade serous carcinoma and examines MYC amplification as a promising surrogate biomarker to guide PARP inhibitor therapy.
Read More
Homologous Recombination Repair Gene Alterations Are Uncommon and Not Prognostic in Molecularly Classified Endometrial Cancer
Posted innews OB/GYN & Women’s Health Oncology

Homologous Recombination Repair Gene Alterations Are Uncommon and Not Prognostic in Molecularly Classified Endometrial Cancer

Posted by MedXY By MedXY 06/08/2026
In a 298-patient endometrial cancer cohort, HRR gene alterations were rare, enriched in aggressive tumor subsets, but did not predict survival or platinum sensitivity beyond integrated molecular classification.
Read More
  • The Economic Burden of Gestational Diabetes and Body Mass Index Changes Between Pregnancies: A Retrospective Cohort Study
  • Assessing Uterine Scar Healing After Consecutive Cesareans: Insights from Sonohysterography on Endometrium-Free Closure Technique
  • Enhanced Prenatal Care Models in Low-Income Latine Populations: Impact on Care Experience in a Randomized Trial
  • Endothelial-to-Mesenchymal Transition: Unlocking New Therapeutic Avenues for Portal Vein Thrombosis in Cirrhosis
  • International Consensus on Measuring and Repairing the Gut Barrier in IBD: Practical guidance for clinical trials
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号
  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology health heart failure hepatocellular carcinoma Hypertension immunotherapy inflammation MASLD mental health metformin Mortality myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prostate cancer public health quality of life randomized clinical trial randomized controlled trial randomized trial risk stratification SGLT2 inhibitors stroke type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in